Molecular integration via allosteric interactions in receptor heteromers. A working hypothesis

Current Opinion in Pharmacology

Volumn 10, Issue 1, 2010, Pages 14-22

  Fuxe, Kjell ^a   Marcellino, Daniel ^a   Leo, Giuseppina ^b   Agnati, Luigi F ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; CANNABINOID 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; HETEROMER; HISTAMINE H3 RECEPTOR; HOMOCYSTEINE; LEVODOPA; MEMBRANE RECEPTOR; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; POLYMER; UNCLASSIFIED DRUG;

ALLOSTERISM; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; DRUG POTENTIATION; DRUG TARGETING; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LOW DRUG DOSE; MOLECULAR INTERACTION; MOSAICISM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; PARKINSON DISEASE; PROTEIN MULTIMERIZATION; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED; SCHIZOPHRENIA;

EID: 72449203291     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.10.010     Document Type: Review

References (48)

1. Agnati L.F., Fuxe K., Zini I., Lenzi P., and Hokfelt T. Aspects on receptor regulation and isoreceptor identification. Med Biol 58 (1980) 182-187
2. Fuxe K., Agnati L.F., Benfenati F., Cimmino M., Algeri S., Hokfelt T., and Mutt V. Modulation by cholecystokinins of 3H-spiroperidol binding in rat striatum: evidence for increased affinity and reduction in the number of binding sites. Acta Physiol Scand 113 (1981) 567-569
3. Agnati L.F., Ferre S., Lluis C., Franco R., and Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol Rev 55 (2003) 509-550
4. Fuxe K., Canals M., Torvinen M., Marcellino D., Terasmaa A., Genedani S., Leo G., Guidolin D., Diaz-Cabiale Z., Rivera A., et al. Intramembrane receptor-receptor interactions: a novel principle in molecular medicine. J Neural Transm 114 (2007) 49-75
5. Fuxe K., Agnati L.F., Benfenati F., Celani M., Zini I., Zoli M., and Mutt V. Evidence for the existence of receptor--receptor interactions in the central nervous system. Studies on the regulation of monoamine receptors by neuropeptides. J Neural Transm Suppl 18 (1983) 165-179
6. Zoli M., Agnati L.F., Hedlund P.B., Li X.M., Ferre S., and Fuxe K. Receptor-receptor interactions as an integrative mechanism in nerve cells. Mol Neurobiol 7 (1993) 293-334
7. Limbird L.E., Meyts P.D., and Lefkowitz R.J. Beta-adrenergic receptors: evidence for negative cooperativity. Biochem Biophys Res Commun 64 (1975) 1160-1168
8. Ferre S., Agnati L.F., Ciruela F., Lluis C., Woods A.S., Fuxe K., and Franco R. Neurotransmitter receptor heteromers and their integrative role in 'local modules': the striatal spine module. Brain Res Rev 55 (2007) 55-67. The authors review for the first time the importance of neurotransmitter receptor heteromers for the integrative activity of the striatal spine module and its impact on the function of the medium spiny neurons of the striatum.
9. Franco R., Casado V., Cortes A., Mallol J., Ciruela F., Ferre S., Lluis C., and Canela E.I. G-protein-coupled receptor heteromers: function and ligand pharmacology. Br J Pharmacol 153 Suppl 1 (2008) S90-98
10. Fuxe K., Marcellino D., Rivera A., Diaz-Cabiale Z., Filip M., Gago B., Roberts D.C., Langel U., Genedani S., Ferraro L., et al. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res Rev 58 (2008) 415-452
11. Agnati L.F., Leo G., Genedani S., Andreoli N., Marcellino D., Woods A., Piron L., Guidolin D., and Fuxe K. Structural plasticity in G-protein coupled receptors as demonstrated by the allosteric actions of homocysteine and computer-assisted analysis of disordered domains. Brain Res Rev 58 (2008) 459-474
12. Ferre S., Baler R., Bouvier M., Caron M.G., Devi L.A., Durroux T., Fuxe K., George S.R., Javitch J.A., Lohse M.J., et al. Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5 (2009) 131-134
13. B receptors-the first 7TM heterodimers. Trends Pharmacol Sci 20 (1999) 396-399
14. Jordan B.A., and Devi L.A. G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399 (1999) 697-700
15. Gines S., Hillion J., Torvinen M., Le Crom S., Casado V., Canela E.I., Rondin S., Lew J.Y., Watson S., Zoli M., et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci U S A 97 (2000) 8606-8611
16. Milligan G., and Smith N.J. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28 (2007) 615-620
17. 2 receptors.
18. Vilardaga J.P., Nikolaev V.O., Lorenz K., Ferrandon S., Zhuang Z., and Lohse M.J. Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol 4 (2008) 126-131. This paper demonstrates the trans-conformational switching mechanism that underlies direct inhibition of receptor activation in this heterodimer. These trans-inhibition phenomena are based on cross-conformational changes constituting a fast way of precluding overstimulation of signaling pathways in a heterodimer.
19. 2 activation through allosteric mechanisms reducing G protein coupling. This novel methodology opens up new possibilities to understand the signaling and pharmacology of distinct heterodimers.
20. Gurevich V.V., and Gurevich E.V. GPCR monomers and oligomers: it takes all kinds. Trends Neurosci 31 (2008) 74-81
21. 2 receptors are located in close molecular proximity in living mammalian cells at physiological levels of expression, consistent with their organization as higher order oligomers at the plasma membrane.
22. Gandia J., Galino J., Amaral O.B., Soriano A., Lluis C., Franco R., and Ciruela F. Detection of higher-order G protein-coupled receptor oligomers by a combined BRET-BiFC technique. FEBS Lett (2008)
23. Carriba P., Navarro G., Ciruela F., Ferre S., Casado V., Agnati L., Cortes A., Mallol J., Fuxe K., Canela E.I., et al. Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 5 (2008) 727-733. The authors combine bioluminescence resonance energy transfer (BRET) and fluorescence resonance energy transfer (FRET) in a technique called sequential BRET-FRET (SRET) that permits identification of heteromers formed by three different proteins. Using SRET, complexes of cannabinoid CB(1), dopamine D(2) and adenosine A(2A) receptors were identified in living cells.
24. Bouvier M., Heveker N., Jockers R., Marullo S., and Milligan G. BRET analysis of GPCR oligomerization: newer does not mean better. Nat Methods 4 (2007) 3-4. Author reply 4. The authors underline the value of BRET in assessing protein-protein interactions in living cells with the use also of additional quantitative approaches. They also point out the need for further studies in native tissues to establish the generality of GPCR dimerization in physiologically relevant systems.
25. Gurevich V.V., and Gurevich E.V. How and why do GPCRs dimerize?. Trends Pharmacol Sci 29 (2008) 234-240
26. Ciruela F., Burgueno J., Casado V., Canals M., Marcellino D., Goldberg S.R., Bader M., Fuxe K., Agnati L.F., Lluis C., et al. Combining mass spectrometry and pull-down techniques for the study of receptor heteromerization. Direct epitope-epitope electrostatic interactions between adenosine A2A and dopamine D2 receptors. Anal Chem 76 (2004) 5354-5363
27. Woods A.S., and Ferre S. Amazing stability of the arginine-phosphate electrostatic interaction. J Proteome Res 4 (2005) 1397-1402
28. Keskin O., Gursoy A., Ma B., and Nussinov R. Principles of protein-protein interactions: what are the preferred ways for proteins to interact?. Chem Rev 108 (2008) 1225-1244
29. Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G., et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452 (2008) 93-97
30. Agnati L.F., Fuxe K., Zoli M., Rondanini C., and Ogren S.O. New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram. Med Biol 60 (1982) 183-190
31. Navarro G., Carriba P., Gandia J., Ciruela F., Casado V., Cortes A., Mallol J., Canela E.I., Lluis C., and Franco R. Detection of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8 (2008) 1088-1097
32. Cabello N., Gandia J., Bertarelli D.C., Watanabe M., Lluis C., Franco R., Ferre S., Lujan R., and Ciruela F. Metabotropic glutamate type 5, dopamine D2 and adenosine A2a receptors form higher-order oligomers in living cells. J Neurochem 109 (2009) 1497-1507. The authors give evidence by the combination of bimolecular fluorescence complementation and bioluminescence resonance energy transfer techniques, as well as the sequential resonance energy transfer technique of the existence of receptor oligomers containing more than two protomers, namely the mGlu(5)R, D(2)R and adenosine A(2A) receptor (A(2A)R) containing. heteromer.
33. Fotiadis D., Liang Y., Filipek S., Saperstein D.A., Engel A., and Palczewski K. Atomic-force microscopy: Rhodopsin dimers in native disc membranes. Nature 421 (2003) 127-128
34. Levoye A., Dam J., Ayoub M.A., Guillaume J.L., Couturier C., Delagrange P., and Jockers R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J 25 (2006) 3012-3023
35. Cabello N., Remelli R., Canela L., Soriguera A., Mallol J., Canela E.I., Robbins M.J., Lluis C., Franco R., McIlhinney R.A., et al. Actin-binding protein alpha-actinin-1 interacts with the metabotropic glutamate receptor type 5b and modulates the cell surface expression and function of the receptor. J Biol Chem 282 (2007) 12143-12153
36. Terrillon S., Barberis C., and Bouvier M. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. Proc Natl Acad Sci U S A 101 (2004) 1548-1553
37. Woods A., Marcellino D., Jackson S.N., Ferre S., Franco R., Agnati L., and Fuxe K. How calmodulin interacts with the adenosine A2A and the dopaminne D2 receptors. J Proteome Res 7 (2008) 3428-3434
38. 2 heteromers, respectively.
39. q/11 activation occurs producing increases in PLC activity and a rapid rise of intracellular calcium levels. This work illustrates how formation of heteromers increases the diversity of signaling pathways that can be used by receptor subtypes.
40. Kachroo A., Orlando L.R., Grandy D.K., Chen J.F., Young A.B., and Schwarzschild M.A. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25 (2005) 10414-10419
41. Ferrada C., Ferre S., Casado V., Cortes A., Justinova Z., Barnes C., Canela E.I., Goldberg S.R., Leurs R., Lluis C., et al. Interactions between histamine H3 and dopamine D2 receptors and the implications for striatal function. Neuropharmacology 55 (2008) 190-197
42. Marcellino D., Carriba P., Filip M., Borgkvist A., Frankowska M., Bellido I., Tanganelli S., Muller C.E., Fisone G., Lluis C., et al. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology 54 (2008) 815-823
43. Carriba P., Ortiz O., Patkar K., Justinova Z., Stroik J., Themann A., Muller C., Woods A.S., Hope B.T., Ciruela F., et al. Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32 (2007) 2249-2259
44. Borgkvist A., Marcellino D., Fuxe K., Greengard P., and Fisone G. Regulation of DARPP-32 phosphorylation by Delta9-tetrahydrocannabinol. Neuropharmacology 54 (2008) 31-35
45. 2 heteromer through the demonstration that this receptor heteromer regulates NMDA-mediated excitation and firing in the striato-pallidal GABA neurons.
46. Rimondini R., Ferre S., Ogren S.O., and Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacology 17 (1997) 82-91
47. Fuxe K., Marcellino D., Woods A.S., Giuseppina L., Antonelli T., Ferraro L., Tanganelli S., and Agnati L.F. Integrated signaling in heterodimers and receptor mosaics of different types of GPCRs of the forebrain: relevance for schizophrenia. J Neural Transm 116 (2009) 923-939
48. Diaz-Cabiale Z., Vivo M., Del Arco A., O'Connor W.T., Harte M.K., Muller C.E., Martinez E., Popoli P., Fuxe K., and Ferre S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett 324 (2002) 154-158